Vitaeris Inc.

Vitaeris Inc. is a biotechnology company focused on developing innovative therapies for patients with rare diseases, leveraging advanced research to create impactful medical solutions. Vitaeris Inc. operates in biotechnology, primarily developing therapies for rare diseases.

The company was founded in 2016 and is headquartered in Vancouver, Canada. In June 2020, CSL Behring agreed to acquire Vitaeris Inc. , with undisclosed financial terms. The firm has participated in 2 deals, with its latest round being a Seed round in which it raised USD 7.

00 mn led by HBM Partners, matching the total amount raised by the company. Vitaeris Inc. specializes in biotherapeutics targeting rare diseases, providing innovative therapies to address unmet medical needs. The company focuses on conditions such as hereditary bleeding disorders and immune deficiencies, developing a range of treatments designed to improve patients' quality of life.

Vitaeris Inc. generates revenue through the commercialization of its biotherapeutic products, engaging in B2B transactions primarily with hospitals and healthcare providers. Products are sold directly and through partnerships, with pricing reflecting the therapeutic area and patient needs. Vitaeris Inc.

is aiming to expand its product offerings and enter new markets, following its acquisition by CSL Behring. The funding from the recent Seed round will support initiatives such as developing new therapies for rare diseases and enhancing market presence, particularly in North America and Europe.